TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Tissue Change During Radiation Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Involvement of sentinel lymph node (presence/absence of tumor cell)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Identification of parathyroid glands by NIR/ICG camera
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of bone mineral accrual
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Who Completed the Intended Bronchoscopic Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Max %fall in FEV1 during late phase asthmatic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence rate of immune-related pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of immune-related colitis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of immune-related hepatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of immune-related nephritis/renal dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of immune-related endocrinopathies
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of immune-related rash (including toxic epidermal necrolysis)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experience at Least 1 Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Meet the TDC Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Meet the TDC Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Meet the TDC Markedly Abnormal Criteria for Safety 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brachial ultrasound FMD scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Movement Imagery Questionnaire-3 (MIQ-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chaotic Motor Imagery Assessment- Hand Rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Assessment- Upper Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lower Extremity Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 90 days mortality
Endpoint domain: Mortality/survival
Primary endpoint: 12 months mortality
Endpoint domain: Mortality/survival
Primary endpoint: Stress (cortisol concentrations and perceived stress)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants Who Selected the Grape-Flavored Fruit Drink
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent of Participants Who Selected the Lower Sugar Granola Snack
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant satisfactory experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Provider satisfactory experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in mean deviation of visual field exams
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Steady-state frequencies of replication-competent CD4+ T cell HIV-1 reservoirs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantitative changes in LLV between 6.5 and 50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative changes in viral diversity during HAART
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognosis of high risk cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lymph nodes harvested
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Sepsis complications
Endpoint domain: Adverse events/effects
Primary endpoint: Improvements in metabolic syndrome status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cut-off value in diagnosing AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relationship between biomarker and clinical symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of positive HBV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Agreement in hemodynamic measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Offset between lateral edge of opacified artery and visualized artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speech recognition in quiet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diurnal differences in global CVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Increase of Cerebrospinal Fluid (CSF) Amyloid Beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in memory deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change on visual analog scale (VAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of short terms walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month change in six-minute walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Red Blood Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Platelet Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time Specific Interdialytic Weight Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time Specific Dietary Sodium Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Impetigo Prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence Rates of Intussusceptions
Endpoint domain: Adverse events/effects
Primary endpoint: Best Overall Response Rate (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time at which the highest drug concentration occurs (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the concentration-time curve from zero time to time of last quantifiable concentration AUC(0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to change of visceral adiposity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time to change of TG/HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients Who Experienced a Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiovascular disease knowledge assessment score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Forced Expiratory Value in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Infection That Requires IV Antibiotics or Re-hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Successful Device Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Functionally Adequate Vesico-urethral Anastomosis Within 21 Days Post-Device Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in ability on Speech and Language Battery
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Objectively confirmed VTE events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of children referred to the study each month meeting eligibility requirements
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the number of patients who receives naloxone prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area under the concentration-time curve (AUC) from time zero to infinity (AUC0-inf) of praliciguat in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of praliciguat in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal elimination half-life (t1/2) of praliciguat in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-endodontic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival without disease at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: success for intended use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: overall operator performance evaluation
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Efficacy of surgical ablation for AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complications associated with the surgical procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Healing of Vesicular Primary Lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Measure of survival
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of Lung Nodule Localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed attack rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Walking characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-reported alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematologic Improvement of Platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Surgeon's Assessment of Procedural Difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Satisfaction With Surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-Surgical Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in SCT (Sodium Chloride Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cellular phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychic profile of parents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to incidence of composite endpoint (Death, Mechanical ventilation, ECMO, Cardiovascular organ support, Renal failure)
Endpoint domain: Mortality/survival
Primary endpoint: Completed Colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Delta IMR post-PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delta IMR pre-PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: a composite of end-stage kidney disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: increasing by 50% of the serum creatinine level from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lumbar Spine Areal Bone Mineral Density (aBMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: MRI T2* assessments in the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effects on Withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accommodation response of the natural lens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measures of Social Function
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: IL8 induction in nasal wash samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants responding to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with Renal toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CO excretion measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Diagnosed With Acromegaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in HbA1c at Week 24 for Double-blind Group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in HbA1c at Week 24 for High Glycemic Group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in endometriosis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TLNOss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TLCOsb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in memory measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Force under the stance limb foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in volume of fibroadenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of fibroadenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appointment Nonadherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: diagnostic of silent myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Healing rates for gastric ulcer patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement or absence of gastric ulcer associated symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Resting and active motor threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor evoke potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical observation of aberrant movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 mcg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measure of Acne stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exhaled breath temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rate of delayed bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Dose Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in number of suicide deaths from baseline
Endpoint domain: Mortality/survival
Primary endpoint: Change in suicidal behaviors from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in suicide ideation from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta Interleukine-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PCI complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Interleukin-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: new dyskinesia attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Defunction ileostomy rate
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of urinary retention necessitating catheterisation
Endpoint domain: Adverse events/effects
Primary endpoint: Tooth status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Total Sperm Count Per Ejaculate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of Confirmed Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maternal Anxious Behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concentration of circulating TAG in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total plasma concentrations of cangrelor and its primary metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving ≥90% inhibition of final platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of safety by evaluating adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Probability of handwashing with soap and water after toilet use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of handwashing with water after toilet use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with abnormal sympathetic-parasympathetic balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average of the usability scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of chronic post thoracotomy pain syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma nevirapine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Number of Asthma Symptom Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2 hour post prandial blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Avoidance of repeat ED visits or hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of the proportion of events
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of adequate, inadequate and avoidable ED-visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of post operative pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptoms of burnout by MBI score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Symptoms of post-traumatic stress disorder by IES and HADS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of units Packed Red Blood Cells (PRBCs) transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Urine colour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Speech Reception Threshold (SRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Word Recognition Score (WRS) at 50 dB HL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Serious Adverse Device Events (SADEs) and Device Failures and Replacements
Endpoint domain: Adverse events/effects
Primary endpoint: electric nociception threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DBI score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Intensity Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C3 levels in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complement deposition in kidneys
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: bacterial contamination (CFU/cm2) of the EVD entry-site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical outcome data on DTRAX Graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children with olfactory disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes